Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F13A1 | P00488 | 1/20 | 0.72 |
| ▸ | TGM2 | P21980 | 1/20 | 0.72 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.59 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.56 |
| ▸ | CDK2 | P24941 | 4/20 | 0.56 |
| ▸ | CCNA1 | P78396 | 4/20 | 0.56 |
| ▸ | PLK4 | O00444 | 2/20 | 0.56 |
| ▸ | CDK1 | P06493 | 2/20 | 0.56 |
| ▸ | AXL | P30530 | 2/20 | 0.56 |
| ▸ | FLT3 | P36888 | 2/20 | 0.56 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.56 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.56 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.56 |
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | GEMIN4 | P57678 | 1/20 | 0.49 |
| ▸ | HSF1 | Q00613 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MITF | O75030 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10150866 | 0.87 | F13A1 (0.72) | F13A1TGM2MKNK2CCNA2CDK2 | |
| SCHEMBL10150862 | 0.87 | F13A1 (0.72) | F13A1TGM2MKNK2CCNA2CDK2 | |
| SCHEMBL14293646 | 0.86 | F13A1 (0.82) | F13A1TGM2MKNK2CCNA2CDK2 | |
| Monocillin Iii SCHEMBL10150121 | 0.86 | HSP90AB1 (0.71) | F13A1TGM2MKNK2CCNA2CDK2 | |
| Monocillin Iii SCHEMBL10150575 | 0.86 | HSP90AB1 (0.71) | F13A1TGM2MKNK2CCNA2CDK2 | |
| Monocillin Iii SCHEMBL10150122 | 0.86 | HSP90AB1 (0.71) | F13A1TGM2MKNK2CCNA2CDK2 | |
| SCHEMBL29711356 | 0.84 | F13A1 (1.00) | F13A1TGM2MKNK2FLT3MKNK1 | |
| SCHEMBL19418496 | 0.83 | F13A1 (0.74) | F13A1TGM2MKNK2CCNA2CDK2 | |
| SCHEMBL19418040 | 0.83 | F13A1 (0.74) | F13A1TGM2MKNK2CCNA2CDK2 | |
| SCHEMBL10150081 | 0.83 | HSP90AB1 (0.76) | F13A1TGM2MKNK2CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2136799-B1 | MACROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES AND HSP90 | UNIV STRASBOURG (FR) | 2017-10-04 | — | — | EP | disclosed |
| US-8450305-B2 | Macrocyclic compounds useful as inhibitors of kinases and HSP90 | UNIVERSITE DE STRASBOURG (FR) | 2013-05-28 | — | — | US | disclosed |
| US-8450305-B2 | Macrocyclic compounds useful as inhibitors of kinases and HSP90 | UNIVERSITE DE STRASBOURG (FR) | 2013-05-28 | — | — | US | disclosed |
| US-20120077775-A1 | MACROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES AND HSP90 | LE CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-03-29 | — | — | US | disclosed |
| US-20120077775-A1 | MACROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES AND HSP90 | LE CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-03-29 | — | — | US | disclosed |
| US-8067412-B2 | analogs of natural products radicicol and pochonins; (oxirane or cyclopropan) 2-benzoxacyclo(di)tetradecin derivatives; inhibition of kinase phosphorylation activity and heat shock proteins; anticarcinogenic, antiinflammatory agent; neurodegenerative diseases; antiallergen | UNIVERSITE DE STRASBOURG (FR) | 2011-11-29 | — | — | US | disclosed |
| US-8067412-B2 | analogs of natural products radicicol and pochonins; (oxirane or cyclopropan) 2-benzoxacyclo(di)tetradecin derivatives; inhibition of kinase phosphorylation activity and heat shock proteins; anticarcinogenic, antiinflammatory agent; neurodegenerative diseases; antiallergen | UNIVERSITE DE STRASBOURG (FR) | 2011-11-29 | — | — | US | disclosed |
| US-20080146545-A1 | Macrocyclic compounds useful as inhibitors of kinases and HSP90 | UNIVERSITE DE STRASBOURG (FR) | 2008-06-19 | — | — | US | disclosed |
| US-20080146545-A1 | Macrocyclic compounds useful as inhibitors of kinases and HSP90 | UNIVERSITE DE STRASBOURG (FR) | 2008-06-19 | — | — | US | disclosed |
| WO-2008021213-A1 | MACROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES AND HSP90 | WINSSINGER NICOLAS (FR) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077775-A1 | MACROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES AND HSP90 | HSP90AB1, HSP90AA1, HSP90AB2P | F13A1 3067/4885TGM2 3060/4885MKNK2 12/4885 |
| US-20080146545-A1 | Macrocyclic compounds useful as inhibitors of kinases and HSP90 | HSP90AB1, HSP90AA1, HSP90AB2P | F13A1 3067/4885TGM2 3060/4885MKNK2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.